Cullinan Therapeutics (CGEM) vs Immatics N.V. (IMTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Immatics N.V. (IMTX) over the past year, gaining 165.4% versus a loss of 20.8%. Over five years, CGEM leads with a -37.5% price change compared with -46.2% for IMTX. Immatics N.V. is the larger company by market cap ($1.13 billion vs $960.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | IMTX |
|---|---|---|
| Share price | $15.63 | $7.45 |
| Market cap | $960.59M | $1.13B |
| 1-day change | -3.82% | -0.67% |
| YTD return | +51.01% | -29.05% |
| 1-year return | +165.37% | -20.83% |
| 5-year return | -37.48% | -46.21% |
| EPS (TTM) | $-3.11 | $-1.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $12.41 |
| 52-week low | $5.85 | $7.31 |
| Distance from 52-week high | -32.60% | -39.97% |
| Average volume | 868.12K | 587.61K |
| Shares outstanding | 61.46M | 152.23M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed IMTX by 186.2 percentage points over the past year.
CGEM vs IMTX FAQ
Which is bigger, Cullinan Therapeutics or Immatics N.V.?
Immatics N.V. (IMTX) is larger, with a market capitalization of $1.13B compared with $960.59M for Cullinan Therapeutics (CGEM).
Which stock has performed better over the past year, CGEM or IMTX?
CGEM returned +165.37% over the past 12 months, compared with -20.83% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Immatics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.